![Dr Mridul Johari on Twitter: "Inclusion body Myositis, where does the name come from? #myositisawareness #myositisresearcher #AcademicTwitter #inclusionbodymyositis https://t.co/JB9vM36kwK" / Twitter Dr Mridul Johari on Twitter: "Inclusion body Myositis, where does the name come from? #myositisawareness #myositisresearcher #AcademicTwitter #inclusionbodymyositis https://t.co/JB9vM36kwK" / Twitter](https://pbs.twimg.com/media/D5tJvBuXoAAld4I.jpg)
Dr Mridul Johari on Twitter: "Inclusion body Myositis, where does the name come from? #myositisawareness #myositisresearcher #AcademicTwitter #inclusionbodymyositis https://t.co/JB9vM36kwK" / Twitter
![Clinical features of patients with inclusion body myositis. (a) Atrophy... | Download Scientific Diagram Clinical features of patients with inclusion body myositis. (a) Atrophy... | Download Scientific Diagram](https://www.researchgate.net/publication/342770624/figure/fig1/AS:919303083786240@1596190343522/Clinical-features-of-patients-with-inclusion-body-myositis-a-Atrophy-of-finger.png)
Clinical features of patients with inclusion body myositis. (a) Atrophy... | Download Scientific Diagram
![Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment - ScienceDirect Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1388245715015643-gr1.jpg)
Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment - ScienceDirect
![Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/dad580fb-1278-4fc7-ae5b-1f405d46bc90/gr1.gif)
Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial - The Lancet Rheumatology
![Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0967586814006195-gr1.jpg)
Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches - ScienceDirect
![Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis | Rheumatology & Autoimmunity Phenotypical statin‐associated immune‐mediated necrotizing myositis with histological features of inclusion body myositis | Rheumatology & Autoimmunity](https://mednexus.org/cms/asset/6d0a655b-66f1-4b5e-93a9-8fc204373491/rai212059-gra-0001.png)